Zoetis Inc. $ZTS Shares Bought by GHP Investment Advisors Inc.

GHP Investment Advisors Inc. lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 152.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,943 shares of the company’s stock after buying an additional 1,777 shares during the quarter. GHP Investment Advisors Inc.’s holdings in Zoetis were worth $459,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZTS. Vanguard Group Inc. raised its position in shares of Zoetis by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company’s stock valued at $6,842,222,000 after purchasing an additional 189,287 shares in the last quarter. Polen Capital Management LLC lifted its stake in Zoetis by 17.6% in the 1st quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company’s stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares in the last quarter. Northern Trust Corp increased its position in Zoetis by 1.2% in the 1st quarter. Northern Trust Corp now owns 6,504,902 shares of the company’s stock worth $1,071,032,000 after purchasing an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Zoetis by 2.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company’s stock valued at $847,293,000 after acquiring an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. lifted its position in shares of Zoetis by 7.6% during the 1st quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company’s stock worth $725,866,000 after buying an additional 312,746 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Up 0.2%

ZTS opened at $144.43 on Tuesday. Zoetis Inc. has a one year low of $139.34 and a one year high of $181.85. The company has a fifty day moving average price of $146.94 and a 200-day moving average price of $153.41. The firm has a market capitalization of $64.01 billion, a P/E ratio of 24.86, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.56 earnings per share. Equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s payout ratio is currently 34.42%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ZTS shares. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. UBS Group reduced their price target on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday, October 20th. Leerink Partnrs cut Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $195.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.